Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell KIR Epitope Mismatch in T-Cell Depleted HSCT
NCT00392782Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2005
- Primary completion
- May 2011
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of peripheral blood stem cells in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Disease-free Survival at 1 year. Started Jul 2005; status: terminated.
02
Drugs
peripheral blood stem cells
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00392782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392782.